Figure 1.
Patient flow diagram showing the number of patients assessed for eligibility, study enrolment and kisspeptin-54 dosing group allocation. Seventy-six patients were screened for participation in the study, of whom 62 women at high risk of ovarian hyperstimulation syndrome (OHSS) were randomized 1:1 to receive either one (Single, n = 31) or two (Double, n = 31) doses of kisspeptin-54 to trigger oocyte maturation.